Growth Hormone Deficiency

Somapacitan demonstrates sustained efficacy, patient preference in treating GHD in children

After 2 years of treatment and a switch from daily growth hormone (GH), somapacitan exhibited sustained efficacy and was preferred by the majority of patients and caregivers, according to findings of a Phase 3 trial. The study, a randomized, multi-national, open-label, controlled parallel group trial, spanned 85 sites across 20...